Hinge Health Inc. shares reached a record high of $93.37 on Wednesday, extending a 60.55% gain over the past 12 months and trading just 1% below its 52-week peak.
The company reported second-quarter revenue of $212.8 million, a 53% increase year-over-year, while earnings per share came in at $0.59, far exceeding Wall Street’s $0.13 estimate. Operating income more than doubled to $62 million, and the operating margin expanded to 29%, up from 19% in the prior-year period.
Analysts at Citizens, Truist Securities and Stifel raised their price targets following the results. Citizens set a target of $107 with a Market Outperform rating, while Truist lifted its target to $112. Stifel raised its target to $96. Hinge Health’s market capitalization stands at $7.25 billion.
The company also reported nearly 50% revenue growth over the trailing twelve months and raised its full-year 2026 revenue and earnings guidance. Hinge Health expanded into gastrointestinal health with the $105 million acquisition of Cylinder Health, announced alongside the earnings release.
The stock’s rally reflects investor confidence in the company’s growth trajectory, driven by strong operational performance and strategic expansion into adjacent health segments.
